Pliant Therapeutics Inc. (PLRX)
Pliant Therapeutics Statistics
Share Statistics
Pliant Therapeutics has 60.85M shares outstanding. The number of shares has increased by 1.02% in one year.
| Shares Outstanding | 60.85M |
| Shares Change (YoY) | 1.02% |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 52.66M |
| Failed to Deliver (FTD) Shares | 339 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 7.54M, so 12.39% of the outstanding shares have been sold short.
| Short Interest | 7.54M |
| Short % of Shares Out | 12.39% |
| Short % of Float | 14% |
| Short Ratio (days to cover) | 13.44 |
Valuation Ratios
The PE ratio is -6.59 and the forward PE ratio is -2.78. Pliant Therapeutics's PEG ratio is 1.36.
| PE Ratio | -6.59 |
| Forward PE | -2.78 |
| PS Ratio | 673.04 |
| Forward PS | 1.5 |
| PB Ratio | 2.25 |
| P/FCF Ratio | -9.07 |
| PEG Ratio | 1.36 |
Enterprise Valuation
Pliant Therapeutics Inc. has an Enterprise Value (EV) of 1.01B.
| EV / Earnings | -6.27 |
| EV / Sales | 640.22 |
| EV / EBITDA | -6.39 |
| EV / EBIT | -5.49 |
| EV / FCF | -8.62 |
Financial Position
The company has a current ratio of 17.72, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.72 |
| Quick Ratio | 17.72 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.34 |
| Cash Flow / Debt | -10.23 |
| Interest Coverage | -145.34 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -37.97%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -37.97% |
| Revenue Per Employee | 9.52K |
| Profits Per Employee | -971.9K |
| Employee Count | 166 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -79.14% in the last 52 weeks. The beta is 1.04, so Pliant Therapeutics's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -79.14% |
| 50-Day Moving Average | 9.62 |
| 200-Day Moving Average | 12.08 |
| Relative Strength Index (RSI) | 27.37 |
| Average Volume (20 Days) | 1.64M |
Income Statement
In the last 12 months, Pliant Therapeutics had revenue of 1.58M and earned -161.34M in profits. Earnings per share was -2.75.
| Revenue | 1.58M |
| Gross Profit | 1.58M |
| Operating Income | -184.15M |
| Net Income | -161.34M |
| EBITDA | -158.23M |
| EBIT | -184.15M |
| Earnings Per Share (EPS) | -2.75 |
Balance Sheet
The company has 63.23M in cash and 11.37M in debt, giving a net cash position of 51.86M.
| Cash & Cash Equivalents | 63.23M |
| Total Debt | 11.37M |
| Net Cash | 51.86M |
| Retained Earnings | -499.75M |
| Total Assets | 445.67M |
| Working Capital | 370.08M |
Cash Flow
In the last 12 months, operating cash flow was -116.36M and capital expenditures -921K, giving a free cash flow of -117.28M.
| Operating Cash Flow | -116.36M |
| Capital Expenditures | -921K |
| Free Cash Flow | -117.28M |
| FCF Per Share | -2 |
Margins
Gross margin is 100%, with operating and profit margins of -11.65K% and -10.21K%.
| Gross Margin | 100% |
| Operating Margin | -11.65K% |
| Pretax Margin | -10.21K% |
| Profit Margin | -10.21K% |
| EBITDA Margin | -10.01K% |
| EBIT Margin | -11.65K% |
| FCF Margin | -7.42K% |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -79.71% |
| FCF Yield | -55.86% |
Analyst Forecast
The average price target for PLRX is $4, which is 15.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 15.9% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -1.4 |
| Piotroski F-Score | 2 |